文献速递乳腺癌

HER2阳性乳腺癌THP新辅助治疗的pCR率及预测因素:EA1181/CompassHER2 pCR二次分析

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
PubMed 文献 · J Clin Oncol · 2026-08-20

EA1181单臂试验评估II/IIIa期HER2阳性乳腺癌患者接受新辅助紫杉类+曲妥珠单抗+帕妥珠单抗(THP)的pCR率及相关因素。2,141例启动THP患者总体pCR率43.8%,HER2+/ER-为63.7%,HER2+/ER+为32.4%。低激素受体表达、HER2 IHC 3+、每周紫杉醇及高HER2DX pCR评分是pCR的独立预测因素。

要点

  • THP新辅助治疗在HER2+/ER-患者中pCR率近三分之二,HER2+/ER+约三分之一。
  • 低ER/PR表达、HER2 IHC 3+、每周紫杉醇及高HER2DX评分预测更高pCR。
  • T3疾病在HER2+/ER-中与较低pCR率相关,其余T/N分期对pCR无显著影响。

核心结论

  • 新辅助THP在HER2+/ER-乳腺癌中pCR率约63.7%,在HER2+/ER+中约32.4%。
  • 低激素受体表达、HER2 IHC 3+、每周紫杉醇及高HER2DX pCR评分是pCR的独立预测因素。

研究设计与样本

  • EA1181(NCT04266249)为单臂试验,评估II/IIIa期HER2阳性乳腺癌患者接受新辅助THP。
  • 患者接受4周期HP联合每周紫杉醇(12周)或多西他赛(每3周4周期),随后手术。
  • 共入组2,175例(HER2+/ER- 781例;HER2+/ER+ 1,394例),其中2,141例启动THP。
  • HER2DX pCR评分在代表性亚组(569例)的诊断活检样本中检测。
  • 采用逻辑回归模型识别与pCR相关的因素。

主要发现

  • 2,141例启动THP患者总体pCR率为43.8%。
  • HER2+/ER-患者pCR率为63.7%,HER2+/ER+患者为32.4%。
  • ER阴性或低表达、PR阴性或低表达、HER2 IHC 3+及每周紫杉醇治疗与更高pCR率相关。
  • 在HER2+/ER-肿瘤中,T3疾病与较低pCR率相关;其他T和N分期对pCR无显著影响。
  • 在569例评估HER2DX pCR评分的患者中,校正临床病理变量后,高评分与更高pCR率独立相关。

关键数值与推荐

  • pCR定义为ypT0/Tis, ypN0。
  • 总体pCR率43.8%(2,141例启动THP患者)。
  • HER2+/ER- pCR率63.7%,HER2+/ER+ pCR率32.4%。
  • HER2DX pCR评分评估 subset 为569例。

临床怎么用

  • THP新辅助方案可为HER2阳性乳腺癌患者提供风险分层依据,尤其HER2+/ER-患者pCR率较高。
  • 低激素受体表达、HER2 IHC 3+、每周紫杉醇及高HER2DX评分可帮助识别更可能从THP中获益的患者。
  • T3疾病在HER2+/ER-患者中pCR率较低,提示需更个体化治疗策略。

局限性

  • EA1181为单臂试验,无对照臂。
  • 主要终点3年无复发生存率数据尚未成熟,待后续报告。
  • HER2DX pCR评分仅在代表性亚组中评估,非全部患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: EA1181 (ClinicalTrials.gov identifier: NCT04266249) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point-3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)-will be reported when data mature. METHODS: Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR. RESULTS: A total of 2,175 patients were enrolled (781 HER2+/estrogen receptor‑negative [ER-]; 1,394 HER2+/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+/ER- and 32.4% in HER2+/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+/ER- tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables. CONCLUSION: Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER- and one third with HER2+/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tung N, Zhao F, DeMichele A, et al. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026. PMID: 42623567. doi:10.1200/JCO-25-02255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。